nach oben

Die Dermatologie

Erschienen in:

01.06.2016 | Psoriasis vulgaris | Leitthema

Pustulöse Psoriasis

verfasst von: P. Weisenseel, D. Wilsmann-Theis, C. Kahl, K. Reich, PD Dr. R. Mössner

Erschienen in: Die Dermatologie | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Eine Reihe pustulöser Hauterkrankungen teilen klinische, pathogenetische und epidemiologische Aspekte mit der Psoriasis vulgaris, und ihre Einordung als eigene klinische Entitäten oder Unterformen der Psoriasis ist weiterhin umstritten, was sich auch in der Vielzahl ihrer Bezeichnungen widerspiegelt. Hierzu gehören die generalisierte pustulöse Psoriasis mit ihren Sonderformen, die Acrodermatitis continua suppurativa, die akute Pustulosis palmoplantaris, die Psoriasis pustulosa palmoplantaris sowie pustulöse Varianten der vorwiegend durch TNF-Blocker getriggerten paradoxen psoriasiformen Dermatitis. In diesem Beitrag werden Erkenntnisse zu Epidemiologie, klinischem Bild, Pathogenese, Genetik und Therapie dieser pustulösen Hauterkrankungen dargestellt.

Capon F (2013) IL36RN mutations in generalized pustular psoriasis: just the tip of the iceberg? J Invest Dermatol 133:2503–2504CrossRefPubMed

Korber A, Mossner R, Renner R et al (2013) Mutations in IL36RN in patients with generalized pustular psoriasis. J Invest Dermatol 133(11):2634–2637CrossRefPubMed

Marrakchi S, Guigue P, Renshaw BR et al (2011) Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 365:620–628CrossRefPubMed

Berki DM, Liu L, Choon SE et al (2015) Activating CARD14 mutations are associated with generalized pustular psoriasis but rarely account for familial recurrence in psoriasis Vulgaris. J Invest Dermatol 135:2964–2970CrossRefPubMed

Brenner M, Molin S, Ruebsam K, Weisenseel P, Ruzicka T, Prinz JC (2009) Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment. Br J Dermatol 161:964–966

Weisenseel P, Reich K (2013) Paradoxical skin reactions under therapy with TNF-alpha antagonists. Z Rheumatol 72:423–428CrossRefPubMed

Robinson A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF, Jr., Kalb RE (2012) Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 67:279-288 (2012)

Imafuku S, Honma M, Okubo Y et al (2016) Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol : doi:/10.1111/1346-8138.13306

Saeki H, Nakagawa H, Ishii T et al (2015) Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 29:1148–1155CrossRefPubMed

10.

Fujisawa T, Suzuki S, Mizutani Y et al (2015) Granulocyte and monocyte adsorption Apheresis for generalized pustular psoriasis: therapeutic outcomes in three refractory patients. Ther Apher Dial 19:336–341CrossRefPubMed

11.

Huffmeier U, Watzold M, Mohr J et al (2014) Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol 170:202–204CrossRefPubMed

12.

Gao QQ, Xi MR, Yao Q (2013) Impetigo Herpetiformis during pregnancy: a case report and literature review. Dermatology 226:35–40CrossRefPubMed

13.

Sugiura K, Oiso N, Iinuma S et al (2014) IL36RN mutations underlie impetigo herpetiformis. J Invest Dermatol 134:2472–2474CrossRefPubMed

14.

Liao PB, Rubinson R, Howard R et al (2002) Annular pustular psoriasis–most common form of pustular psoriasis in children: report of three cases and review of the literature. Pediatr Dermatol 19:19–25CrossRefPubMed

15.

Albert A, Hein R, Ring J et al (2007) Erythema annulare centrifugum-like psoriasis cum pustulatione. Hautarzt 58:769–773CrossRefPubMed

16.

Stadler R, Orfanos CE (1981) Erythema anulare centrifugum with pustulation. Successful oral retinoid therapy. Hautarzt 32:564–566PubMed

17.

Vocks E, Worret WI, Ring J (2003) Erythema annulare centrifugum-type psoriasis: a particular variant of acute-eruptive psoriasis. J Eur Acad Dermatol Venereol 17:446–448CrossRefPubMed

18.

Lo SA, Brancaccio G, Puca RV et al (2012) Etanercept in the treatment of generalized annular pustular psoriasis. Ann Dermatol 24:233–234CrossRef

19.

Setta-Kaffetzi N, Simpson MA, Navarini AA et al (2014) AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet 94:790–797CrossRefPubMedPubMedCentral

20.

Wilsmann-Theis D, Hagemann T, Dederer H et al (2004) Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0.1 % ointment. Br J Dermatol 150:1194–1197CrossRefPubMed

21.

Sehgal VN, Verma P, Sharma S et al (2011) Acrodermatitis continua of Hallopeau: evolution of treatment options. Int J Dermatol 50:1195–1211CrossRefPubMed

22.

Bacharach-Buhles M, el-Gammal S, Altmeyer P (1993) The pustular bacterid (Andrews). Are there clinical criteria for differentiating from psoriasis pustulosa palmaris et plantaris? Hautarzt 44:221–224PubMed

23.

Burge SM, Ryan TJ (1985) Acute palmoplantar pustulosis. Br J Dermatol 113:77–83CrossRefPubMed

24.

Hellgren L, Mobacken H (1971) Pustulosis palmaris et plantaris. Prevalence, clinical observations and prognosis. Acta Derm Venereol 51:284–288PubMed

25.

O’Doherty CJ, MacIntyre C (1985) Palmoplantar pustulosis and smoking. Br Med J (Clin Res Ed) 291:861–864CrossRef

26.

Enfors W, Molin L (1971) Pustulosis palmaris et plantaris. A follow-up study of a ten-year material. Acta Derm Venereol 51:289–294PubMed

27.

Becher G, Jamieson L, Leman J (2015) Palmoplantar pustulosis–a retrospective review of comorbid conditions. J Eur Acad Dermatol Venereol 29:1854–1856CrossRefPubMed

28.

Brunasso AM, Puntoni M, Aberer W et al (2013) Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study. Br J Dermatol 168:1243–1251CrossRefPubMed

29.

Farley E, Masrour S, McKey J et al (2009) Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol 60:1024–1031CrossRefPubMed

30.

Michaelsson G, Kristjansson G, Pihl LI et al (2007) Palmoplantar pustulosis and gluten sensitivity: a study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten-free diet. Br J Dermatol 156:659–666CrossRefPubMed

31.

Benhamou CL, Chamot AM, Kahn MF (1988) Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO). A new syndrome among the spondyloarthropathies? Clin Exp Rheumatol 6:109–112PubMed

32.

Nguyen MT, Borchers A, Selmi C et al (2012) The SAPHO syndrome. Semin Arthritis Rheum 42:254–265CrossRefPubMed

33.

Yamamoto T (2011) Triggering role of focal infection in the induction of extra-palmoplantar lesions and pustulotic arthro-osteitis associated with palmoplantar pustulosis. Adv Otorhinolaryngol 72:89–92PubMed

34.

Weisenseel P, Kuznetsov AV, Ruzicka T et al (2007) Palmoplantar pustulosis is not inevitably associated with antigliadin antibodies. Br J Dermatol 156:1399–1400CrossRefPubMed

35.

Agner T, Sindrup JH, Hoier-Madsen M et al (1989) Thyroid disease in pustulosis palmoplantaris. Br J Dermatol 121:487–491CrossRefPubMed

36.

Eriksson MO, Hagforsen E, Lundin IP et al (1998) Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol 138:390–398CrossRefPubMed

37.

Murakami M, Ohtake T, Horibe Y et al (2010) Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. J Invest Dermatol 130:2010–2016CrossRefPubMed

38.

Uehara M, Ofuji S (1974) The morphogenesis of pustulosis palmaris et plantaris. Arch Dermatol 109:518–520CrossRefPubMed

39.

Murakami M, Hagforsen E, Morhenn V et al (2011) Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol 20:845–847CrossRefPubMed

40.

Murakami M, Kaneko T, Nakatsuji T et al (2014) Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis. PLoS ONE 9:e110677CrossRefPubMedPubMedCentral

41.

Hagforsen E, Edvinsson M, Nordlind K et al (2002) Expression of nicotinic receptors in the skin of patients with palmoplantar pustulosis. Br J Dermatol 146:383–391CrossRefPubMed

42.

Yoshizaki T, Bandoh N, Ueda S et al (2009) Up-regulation of CC chemokine receptor 6 on tonsillar T cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris. Clin Exp Immunol 157:71–82CrossRefPubMedPubMedCentral

43.

Ueda S, Takahara M, Tohtani T et al (2010) Up-regulation of ss1 integrin on tonsillar T cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis Palmaris et Plantaris. J Clin Immunol 30:861–871CrossRefPubMed

44.

Asumalahti K, Ameen M, Suomela S et al (2003) Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 120:627–632CrossRefPubMed

45.

Setta-Kaffetzi N, Navarini AA, Patel VM et al (2013) Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol 133:1366–1369CrossRefPubMed

46.

Mossner R, Frambach Y, Wilsmann-Theis D et al (2015) Palmoplantar pustular psoriasis is associated with Missense variants in CARD14, but not with loss-of-function mutations in IL36RN in european patients. J Invest Dermatol 135:2538–2541CrossRefPubMed

47.

Kingo K, Mossner R, Koks S et al (2007) Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. Br J Dermatol 156:646–652CrossRefPubMed

48.

Wu W, Debbaneh M, Moslehi H et al (2014) Tonsillectomy as a treatment for psoriasis: a review. J Dermatolog Treat 25:482–486CrossRefPubMed

49.

Kragballe K, Larsen FG (1991) A hydrocolloid occlusive dressing plus triamcinolone acetonide cream is superior to clobetasol cream in palmo-plantar pustulosis. Acta Derm Venereol 71:540–542PubMed

50.

Marsland AM, Griffiths CE (2001) Treatments for chronic palmoplantar pustular psoriasis. Skin Therapy Lett 6:3–5PubMed

51.

Umezawa Y, Nakagawa H, Tamaki K (2015) Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: A randomized, double-blind, placebo-controlled trial. J Dermatol 43:288CrossRefPubMed

52.

Muro M, Kawakami H, Matsumoto Y et al (2015) Topical combination therapy with vitamin D and corticosteroid ointment for palmoplantar pustulosis: A prospective, randomized, left-right comparison study. J Dermatolog Treat 27:51CrossRefPubMed

53.

Sevrain M, Richard MA, Barnetche T et al (2014) Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion. J Eur Acad Dermatol Venereol 28(Suppl 5):13–16CrossRefPubMed

54.

Layton AM, Sheehan-Dare R, Cunliffe WJ (1991) A double-blind, placebo-controlled trial of topical PUVA in persistent palmoplantar pustulosis. Br J Dermatol 124:581–584CrossRefPubMed

55.

Marsland AM, Chalmers RJ, Hollis S et al (2006) Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev CD001433: doi:/10.1002/14651858.cd001433.pub2PubMed

56.

Lassus A, Geiger JM (1988) Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol 119:755–759CrossRefPubMed

57.

Wilken R, Sharma A, Patel F et al (2015) Successful treatment of palmoplantar pustulosis with isotretinoin. Dermatol Online J 21

58.

Reich K, Graff O, Mehta N (2016) Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomised Phase II study. Br J Dermatol : doi:10.1111/bjd.14401

59.

Irla N, Navarini AA, Yawalkar N (2012) Alitretinoin abrogates innate inflammation in palmoplantar pustular psoriasis. Br J Dermatol 167:1170–1174CrossRefPubMed

60.

Adisen E, Tekin O, Gulekon A et al (2009) A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. J Eur Acad Dermatol Venereol 23:814–819CrossRefPubMed

61.

Stanford CW, Kollipara R, Melookaran AM et al (2014) Palmoplantar pustular psoriasis following initiation of a beta-blocker: disease control with low-dose methotrexate. Cutis 94:153–155PubMed

62.

Reitamo S, Erkko P, Remitz A et al (1993) Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo-controlled study. Arch Dermatol 129:1273–1279CrossRefPubMed

63.

Erkko P, Granlund H, Remitz A et al (1998) Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis. Br J Dermatol 139:997–1004CrossRefPubMed

64.

Stander H, Stadelmann A, Luger T et al (2003) Efficacy of fumaric acid ester monotherapy in psoriasis pustulosa palmoplantaris. Br J Dermatol 149:220–222CrossRefPubMed

65.

Bissonnette R, Nigen S, Langley RG et al (2014) Increased expression of IL-17 A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol 28:1298–1305CrossRefPubMed

66.

Robinson A, Van Voorhees AS, Hsu S et al (2012) Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 67:279–288CrossRefPubMed

67.

Bissonnette R, Poulin Y, Bolduc C et al (2008) Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol 7:940–946PubMed

68.

Au SC, Goldminz AM, Kim N et al (2013) Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. J Dermatolog Treat 24:179–187CrossRefPubMed

69.

Tillack C, Ehmann LM, Friedrich M et al (2014) Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17 A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 63:567–577CrossRefPubMed

70.

Perez-Zafrilla B, Angel DM, Carmona L (2008) Adverse reactions related to the administration of TNF inhibitors. analysis of a registry of biologic therapy. Reumatol Clin 4:90–95CrossRefPubMed

71.

Navarro R, Dauden E (2014) Clinical management of paradoxical psoriasiform reactions during TNF- alpha therapy. Actas Dermosifiliogr 105:752–761CrossRefPubMed

72.

Collamer AN, Battafarano DF (2010) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 40:233–240CrossRefPubMed

73.

Shmidt E, Wetter DA, Ferguson SB et al (2012) Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 67:e179–e185CrossRefPubMed

74.

Palucka AK, Blanck JP, Bennett L et al (2005) Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 102:3372–3377CrossRefPubMedPubMedCentral

75.

Nestle FO, Conrad C, Tun-Kyi A et al (2005) Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 202:135–143CrossRefPubMedPubMedCentral

76.

Friedrich M, Tillack C, Wollenberg A et al (2014) IL-36gamma sustains a proinflammatory self-amplifying loop with IL-17 C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn’s disease. Inflamm Bowel Dis 20:1891–1901CrossRefPubMed

77.

Denadai R, Teixeira FV, Steinwurz F et al (2013) Induction or exacerbation of psoriatic lesions during anti-TNF-alpha therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis 7:517–524CrossRefPubMed

78.

Gregoriou S, Kazakos C, Christofidou E et al (2011) Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis. Eur J Dermatol 21:104–105PubMed

79.

Wenk KS, Claros JM, Ehrlich A (2012) Flare of pustular psoriasis after initiating ustekinumab therapy. J Dermatolog Treat 23:212–214CrossRefPubMed

80.

Hay RA, Pan JY (2014) Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy. Clin Exp Dermatol 39:751–752CrossRefPubMed

81.

Laino L, DiCarlo A (2011) Palmoplantar pustular psoriasis: clinical and video thermographic evaluation before and after topical tacrolimus treatment. Arch Dermatol 147:760CrossRefPubMed

82.

Hayama K, Inadomi T, Fujisawa D et al (2010) A pilot study of medium-dose cyclosporine for the treatment of palmoplantar pustulosis complicated with pustulotic arthro-osteitis. Eur J Dermatol 20:758–762PubMed

83.

Wozel G, Vitez L (2008) Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab. Acta Derm Venereol 88:169–170CrossRefPubMed

84.

Morales-Munera C, Vilarrasa E, Puig L (2013) Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. Br J Dermatol 168:820–824CrossRefPubMed

85.

Gerdes S, Franke J, Domm S et al (2010) Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol 163:1116–1118CrossRefPubMed

86.

Bertelsen T, Kragballe K, Johansen C et al (2014) Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis. Int J Dermatol 53:e464–e466CrossRefPubMed

Titel: Pustulöse Psoriasis
verfasst von: P. Weisenseel
D. Wilsmann-Theis
C. Kahl
K. Reich
PD Dr. R. Mössner
Publikationsdatum: 01.06.2016
Verlag: Springer Berlin Heidelberg
Schlagwörter: Psoriasis vulgaris
Pustulöse Erkrankungen
Pustulöse Psoriasis
Pustulosis palmoplantaris
Impetigo contagiosa
Erschienen in: Die Dermatologie / Ausgabe 6/2016
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI: https://doi.org/10.1007/s00105-016-3804-4

Passend zum Thema

Die entscheidende Rolle des Mikrobioms bei atopischer Dermatitis

Bei atopischer Dermatitis besteht eine direkte Korrelation des Schweregrad der Erkrankung und einer verminderten Diversität des Mikrobioms. Studiendaten zeigen, dass durch eine Behandlung mit Emollienzien plus, die Besiedelung mit Staphylokokken reduziert und das Mikrobiom stabilisiert werden kann.

Welche Bedeutung hat das Mikrobiom bei Wundheilung und AD?

Warum hat das Mikrobiom der Haut in den letzten Jahren in der Wissenschaft an enormer Bedeutung gewonnen? Welche Möglichkeiten ergeben sich dadurch für die Behandlung bei Hautkrankheiten wie atopischer Dermatitis und der Wundheilung? Dies erläutert Prof. Thomas Luger im Interview.

Neueste Erkenntnisse zum Hautmikrobiom: vier Experten im Gespräch

Content Hub

Die Experten Prof. Luger (Münster), Prof. Zuberbier (Berlin), Prof. Thaçi (Lübeck) und PD Dr. Jansen (Essen) erörtern im von La Roche Posay unterstützen Expertenworkshop die Bedeutung des Mikrobioms für verschiedene Hautkrankheiten wie atopische Dermatitis, Akne oder Rosazea.

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Systemische Therapien der Psoriasis und Psoriasisarthritis

Panorama Dermatologische Praxis

Psoriasis

Psoriasis in besonderen Lokalisationen

CME: Therapie des Basalzellkarzinoms

Metronidazol in Magistralrezepturen

Passend zum Thema

Die entscheidende Rolle des Mikrobioms bei atopischer Dermatitis

Welche Bedeutung hat das Mikrobiom bei Wundheilung und AD?

Neueste Erkenntnisse zum Hautmikrobiom: vier Experten im Gespräch